Advertisement

Search Results

Advertisement



Article Topics

Your search for Kieron Dunleavy, MD matches 4 pages

Showing 1 - 4


lymphoma

Kieron M. Dunleavy, MD, on B-Cell Malignancies: Novel-Novel Drug Combinations

Kieron M. Dunleavy, MD, of George Washington University, discusses the need for drug combinations to improve lymphoma therapy, despite unexpected toxicities, as our understanding of the molecular biology grows.

lymphoma

Kieron M. Dunleavy, MD, on Lymphomas: Genomics and Genetics

Kieron M. Dunleavy, MD, of the National Cancer Institute, discusses the genomic landscape of aggressive lymphomas and how this is informing therapy decisions.

lymphoma

Kieron Dunleavy, MD, on Burkitt Lymphoma: Preliminary Report of the DA-EPOCH-R Trial

Kieron Dunleavy, MD, of the National Cancer Institute, discusses a multi-center trial that set out to validate the effectiveness of DA-EPOCH-R-based therapy and whether a risk-adapted approach using the regimen is beneficial for patients with Burkitt lymphoma (Abstract 342).

lymphoma

NIH Trial Shows Promising Results in Treating Primary Mediastinal B-cell Lymphoma

Patients with primary mediastinal B-cell lymphoma who received infusions of chemotherapy, but who did not have radiation therapy to the mediastinum, had excellent outcomes, according to clinical trial results.  Until now, most standard treatment approaches for patients with this type of...

Advertisement

Advertisement



Advertisement